Mocco J, Zacharia Brad E, Komotar Ricardo J, Connolly E Sander
Department of Neurosurgery, Columbia University, New York, New York 10032, USA.
Neurosurg Focus. 2006 Sep 15;21(3):E9. doi: 10.3171/foc.2006.21.3.9.
In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.
为了帮助阐明目前脑血管痉挛的药物治疗现状,作者回顾了关于动脉瘤性蛛网膜下腔出血(SAH)后用于治疗脑血管痉挛的既定药物治疗的相关文献,并讨论了新兴的研究领域。尽管在动脉瘤性SAH的治疗方面取得了进展,但脑血管痉挛仍然是一种常见的并发症,并且与出血后前2周内死亡风险增加1.5至3倍相关。目前正在使用或正在研究多种药物、药理学和手术治疗方法,试图逆转脑血管痉挛,但只有少数方法已被证明是有效的。尽管对其病理生理学已经有了很多了解,但脑血管痉挛的治疗仍然是一个难题。尽管迄今为止,对SAH诱导的脑血管痉挛病理生理学的了解不足阻碍了治疗干预措施的发展,但目前的研究努力有望最终产生新的药物治疗方法。